Genomic test 'exceptional' drug response for bladder cancer

According to a recent report published in the journal Cancer Discovery finds out that the patients having advanced bladder cancer in a phase I trial have to complete the initial response for 14 months with combination of drugs everolimus and pazopanib. Further the study advanced to see the tumor response dramatically. The investigators thought of completing the sequencing and coding regions of tumor genome. This research included about 25,000 genes, and found two mutations in mTOR. They also made a catalogue of activated genome alterations in the mTOR pathway. The first author of the research, Nikhil Wagle, M.D., of Dana-Farber Cancer Institute explains, “Studying exceptional responders can help us understand the specific reasons why some tumors are highly sensitive to certain anticancer agents. We can use that information to identify patients whose tumors have genetic alterations similar to those found in exceptional responders, and treat them with those same agents.”